MADRID (Reuters) – the pharmaceutical Almirall said on Monday that its net profit fell by 67.8 percent to 27 million euros in the first six months of the year, in some accounts marked by a continued decline in sales due to the saving in government health spending measures Spanish.

“the first half of 2012 has been marked by different levels of prices compared with the same period of the previous year, as a result of the containment of expenditure on health measures and to promote the use of generic drugs approved by the Government of Spain”, said the group in a communique to the CNMV.

the Group’s net sales fell a 12.3 per cent to 374 million euros, while operating (ebitda) gross profit fell a 54 per cent to 51.1 million euros.

the laboratory will explain the annual accounts to the analysts in a teleconference to the 1000, local time, after that the Group achieved approval for its drug aclidinio in Europe and the United States for the treatment of the so-called “smokers cough”, which is expected report you income in the last quarter of the year.

analysts highlighted the weakness of the market Spanish from Almirall, which has weighed down his account of results.

“results we have not liked. it is true that the quarter that comes will have milestones of Aclidinium and 4T12 the first sales, but the domestic business data are devastating”, said Banesto bag in a note to clients.

A las 09: 34 hours, the actions of the pharmaceutical climbed 1.13 percent to 6.24 euros, in line with the market and after strong rises last week after aclidinio. regulatory approval

in uw persbericht Almirall zei dat het de prognoses voor 2012 opnieuw.